Compare Biogen Inc (BIIB) vs Marathon Digital Holdings Inc (MARA) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

MARA Holdings trades at $9.675, down 1.2% on the day, with a bearish technical signal and negative earnings trends. The company reported a Q2 2026 net loss of $1.60 per share, missing estimates, while revenue declined to $804 million in 2026. Despite a 50% analyst buy rating and a $16.08 consensus price target, profitability remains challenged with a -429.71% net income margin. Recent news highlights a strategic pivot toward AI digital infrastructure amid Bitcoin mining headwinds.

The outlook is mixed: valuation ratios like P/E of 3.37 suggest potential undervaluation, but persistent losses and high debt-to-asset ratio of 49.43% pose significant risks. Upside depends on successful execution of the AI infrastructure strategy, while downside risks include continued earnings misses and cryptocurrency market volatility.